Fulcrum Therapeutics(US:FULC) Globenewswire·2025-10-22 12:54Core Viewpoint - Fulcrum Therapeutics, Inc. is set to release its third quarter 2025 financial results on October 29, 2025, and will host a conference call to discuss these results and recent corporate developments [1]. Company Overview - Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules aimed at improving the lives of patients with genetically defined rare diseases [3]. - The company's lead clinical program is pociredir, a small molecule designed to increase fetal hemoglobin (HbF) expression for treating sickle cell disease (SCD) [3]. - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression, addressing the root cause of gene mis-expression [3]. Conference Call Details - Individuals interested in the conference call can register online to receive dial-in details and a unique PIN for access [2]. - An audio webcast will be available through the Investor Relations section of the company's website, with an archived replay accessible after the live event [2].